The DAD study: a large European database looks at heart attacks

A mostly European database called DAD (the Data collection on Adverse events of anti-HIV Drugs) has enrolled more than 33,000 HIV positive people in an attempt to try to find out more about uncommon side effects. The DAD study is currently ongoing.

Prior analyses of DAD have revealed that there appears to be an increased risk of cardiovascular disease (CVD) in some people who have used protease inhibitors. DAD has accumulated enough data and monitored the health of people long enough that it can report clear results about the use of the following drugs and their association with CVD:

- protease inhibitors – indinavir (Crixivan), lopinavir (in Kaletra), nelfinavir (Viracept) and saquinavir (Invirase)
- non-nukes – efavirenz (Sustiva) and nevirapine (Viramune)
- nukes – AZT (zidovudine, Retrovir), d4T (stavudine, Zerit), ddI (didanosine, Videx), ddC, 3TC (lamivudine), abacavir (Ziagen) and tenofovir (Viread)

For the current analysis, DAD monitored at least 33,308 HIV positive participants until February 2008 or until they developed their first heart attack. Of this total, here are the outcomes:

- no heart attack - 32,728 people
- heart attack - 580 people

Roughly 2% of people in the DAD study developed a heart attack. At the time of their heart attack, the average profile of the 580 people was as follows:

- 9% female, 91% male
- age - 49 years
- 75% had higher-than-normal levels of lipids in the blood
- 45% were currently smoking tobacco
- 30% were former smokers
- 17% had diabetes
- 14% had a family history of cardiovascular disease
- 36% used lipid-lowering therapy

Results

- Nukes – there was a trend toward an increased risk of heart attack the longer abacavir was used. Similar findings were seen with AZT. DAD researchers reported that exposure to ddI was linked to an increased risk of heart attack.
- Non-nukes – no association with a heart attack was detected
- Protease inhibitors – exposure to indinavir or lopinavir-ritonavir was associated with an increased risk of heart attack. Use of these drugs increased the risk by 13%.

Caution needed

Bear in mind that DAD is an observational study and such studies are best at finding associations but cannot prove cause and effect. Also, 20% of people who had a heart attack in the DAD study had had a previous heart attack. What this disclosure by the DAD researchers means for their conclusions is not yet clear. It is possible that the DAD researchers may have inadvertently biased their interpretation of the data by including people in their analysis who had more than one heart attack.
REFERENCE:

Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at: